Gloria Melanie 4

What Happened

• Gloria Melanie, Chief Operating Officer of Immunovant (IMVT), sold 8,722 shares on April 8, 2026 in open-market transactions for a total of approximately $216,567. The filing reports a weighted-average price of $24.83 per share (individual sale prices ranged $24.54–$25.39). This was a sale (not a purchase) and appears to be a routine tax-withholding sale tied to RSU vesting rather than a discretionary market-timing trade.

Key Details

• Transaction date(s): April 8, 2026; Form 4 filed April 10, 2026 (appears timely).
• Price: Weighted average $24.83; individual prices ranged $24.54–$25.39 (per footnote F2).
• Shares sold: 8,722; total proceeds ≈ $216,567.
• Shares owned after transaction: Not specified in the supplied excerpt of the filing.
• Notable footnotes:
  • F1: These shares were sold to satisfy tax withholding upon settlement of RSUs. The reporting person received 76,181 RSUs on April 1, 2025, of which 19,045 vested on April 1, 2026. The issuer elected a mandatory "sell to cover" for tax obligations, so the sale was not a discretionary trade.
  • F2: Price is a weighted average; full breakdown of shares sold at each price is available on request (per footnote).
• Filing timeliness: Filed April 10 for an April 8 transaction — within the typical two-business-day Form 4 window.

Context

• This was a sell-to-cover tied to RSU vesting (a common administrative sale to cover taxes). Such sales generally do not signal the insider’s view on company prospects in the same way that voluntary open-market purchases might.